Sobti Ranbir C, Parashar Kamana, Kaur Raminder, Capalash Neena
Department of Biotechnology, Panjab University, Chandigarh, India.
J Environ Pathol Toxicol Oncol. 2002;21(1):79-85.
Human papillomavirus (HPV) was detected in 85% and 63.6% of patients with invasive cervical cancer and minor cervical abnormalities, respectively. HPV-16 was the dominant type in both groups of women. Because of the high oncogenic potential of HPV-16 and the greater chance of its persistence, a follow-up of cases with minor cervical abnormalities harboring HPV-16 is warranted in order to observe the progression of the lesion. As many as 61.5% of the cases with invasive cervical cancer were found to have higher levels of serum p53 protein than did healthy controls. None of the patients had antibodies against the overexpressed p53. This suggests that, even if mutated, the p53 protein may not be immunogenic in all cases. An inverse relationship between the presence of HPV and the alteration in p53 expression was observed in 71.43% of the cases. This could mean the loss of p53 function as a result of either HPV-E6-mediated degradation or mutation in the p53 gene.
在浸润性宫颈癌患者和轻度宫颈异常患者中，人乳头瘤病毒（HPV）的检出率分别为85%和63.6%。HPV-16是这两组女性中的主要类型。由于HPV-16具有较高的致癌潜力且持续存在的可能性更大，因此有必要对携带HPV-16的轻度宫颈异常病例进行随访，以观察病变的进展情况。发现高达61.5%的浸润性宫颈癌病例血清p53蛋白水平高于健康对照。所有患者均没有针对过表达p53的抗体。这表明，即使p53蛋白发生了突变，在所有情况下也可能没有免疫原性。在71.43%的病例中观察到HPV的存在与p53表达改变之间呈负相关。这可能意味着由于HPV-E6介导的降解或p53基因的突变导致p53功能丧失。
